ClinicalTrials.gg
RecruitingNCT05250791FLICORUpdated Jun 9, 2023

Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome

An interventional study of Lidocaine hydrochloride 2% for injection and 0.9% sterile Sodium Chloride solution for injection in Colorectal Cancer, Quality of Life and Recurrent Cancer, sponsored by Imperial College London. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing lidocaine in Colorectal Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Lidocaine · Colorectal Neoplasms.

Planned enrollment
10th of 13
50 · median 77
Started
2023
with 3 others
No phase
7 of 13
2 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Imperial College London

Among the 13 studies testing lidocaine in Colorectal Neoplasms, this one is the 10th largest by planned enrollment, is one of 4 that started in 2023, is one of 7 with no phase, and was the 9th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 13 studies testing lidocaine in Colorectal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing lidocaine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This feasibility (small) study aims to see if it is possible to run a large study looking at the effect of lidocaine on large bowel cancer recurrence after surgery in the NHS hospitals.

Read the detailed description

Strong preclinical evidence suggests that lidocaine, a type of local anaesthetic commonly used, could potentially reduce cancer recurrence if given during cancer surgery. This study will evaluate the feasibility of conducting a study comparing intravenous lidocaine infusion versus placebo administration for 24 hours from the start of general anaesthesia. The specific population will be any stage 2 or 3 colon or rectal cancer patient undergoing elective laparoscopic colorectal cancer surgery to look at postoperative cancer outcomes in two NHS settings. This study will explore the acceptability, facilitators and potential barriers of recruiting cancer patients, with possible anxieties of a new cancer diagnosis about to have major surgery along with other potential feasibility issues. It will also assess if follow-up and outcome data collection can be streamlined with usual care processes as much as possible and to guide the future definitive trial.

The project will:

  1. Perform a feasibility study. This will be similar in design to the future bigger study and will see:

    • if there are any problems in giving lidocaine;
    • if patients and clinicians would be happy to take part in a study using a design where some patients get the drug and others get a non-active substance (known as placebo);
    • how many patients can we get from the different types and stages of bowel cancer;
    • if patients can be followed up successfully;
    • if we can collect all the data that we would need;
    • what measures might work well for the future study;
  2. Look to see if blood tests can give some idea on how lidocaine might work in patients and if it can be confirmed in the bigger study.

The study will involve a small number of patients getting either lidocaine or placebo, and:

  • filling in questionnaires to measure quality of life;
  • follow up phone call at 6 and 12 months after surgery;
  • having their records looked at to see if cancer comes back;
  • both patients and clinicians to fill in a feedback questionnaire to see how they get on with the study processes;
  • having extra blood tests before and after they finish the lidocaine/placebo infusion.
03

Conditions studied

  • Colorectal Cancer
  • Quality of Life
  • Recurrent Cancer

Keywords

  • Perioperative
  • Intravenous lidocaine
  • cancer recurrence
  • colorectal cancer
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 and above, undergoing laparoscopic surgery with stage 2 or 3 colon cancer
  • Age 18 and above, undergoing laparoscopic surgery with stage 2 or 3 rectal cancer
  • Ability and willingness to consent

Exclusion criteria

Exclusion Criteria:

  • Stage 1 and stage 4 colon or rectal cancer
  • Palliative surgery with no curative intent
  • Extensive comorbidities, i.e. (ASA) Score IV
  • Patients with known or suspected allergy to lidocaine
  • Patients who are currently pregnant* or breastfeeding
  • Patients who are likely to have adverse effects from the accumulation of intravenous lidocaine:

    • current liver disease with a liver function outside the normal laboratory range
    • current renal failure ( \<30)
    • epilepsy
    • cardiac conduction abnormalities based on history and confirmed by
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    lidocaine

    An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.

    Drug: Lidocaine hydrochloride 2% for injection

  • Placebo comparator
    0.9% sterile Sodium Chloride solution for injection

    An equivalent infusion rate (ml) of placebo will be administered following the induction of anaesthesia over 20 minutes followed by hourly equivalent intravenous infusion in ml/hr of placebo with a maximum rate of 6mls/hr (equivalent of 120mg/hour for lidocaine) for 24 hours.

    Drug: 0.9% sterile Sodium Chloride solution for injection

Interventions

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.

    Also known as: Xylocaine

  • Drug0.9% sterile Sodium Chloride solution for injection

    Administered as lidocaine

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Feasibility of recruitment

    The number of eligible patients and the actual number recruited for colon and rectal cancer with stage 2 or 3.

    Time frame: Baseline

  2. Trial retention

    The number of participants who consent to participate who remain in the study until the end of follow up at 12 months.

    Time frame: 12 months post randomisation

  3. The completion of data collection instruments

    on eCRF

    Time frame: 6 months post randomisation

  4. The completion of data collection instruments

    on eCRF

    Time frame: 12 months post randomisation

  5. Participant's feedback of study experiences

    10 questions close-ended questionnaire with optional free text relating to informed consent procedures, the information given, the recruitment process and any suggestions for improvement.

    Time frame: Day 3 hospital stay

  6. Clinical staff feedback of study experiences

    10 questions close-ended questionnaire with optional free text relating to informed consent procedures, the information given, the recruitment process and any suggestions for improvement.

    Time frame: Day 3 hospital stay

  7. Patients' reasons to refuse consent.

    Patients who refuse consent will be asked for their reasons at the point of recruitment only

    Time frame: Baseline

  8. Clinicians' reasons for not recruiting patients.

    Clinicians will be asked their reasons for not recruiting patients

    Time frame: Screening

Secondary outcomes

  1. Disease-free survival

    Cancer recurrence and death from any cause

    Time frame: 12-months post randomisation

  2. Completion of EQ-5D-5L

    The completeness of responses to the health-related quality of life questionnaire, EQ- 5D-5L which would be the outcome measure used in an economic evaluation as part of the definitive trial.

    Time frame: Baseline

  3. Completion of EQ-5D-5L

    The completeness of responses to the health-related quality of life questionnaire, EQ- 5D-5L which would be the outcome measure used in an economic evaluation as part of the definitive trial.

    Time frame: 6 months post randomisation

  4. Completion of EQ-5D-5L

    The completeness of responses to the health-related quality of life questionnaire, EQ- 5D-5L which would be the outcome measure used in an economic evaluation as part of the definitive trial.

    Time frame: 12-months post randomisation

  5. Completion of the cancer-specific quality of life questionnaires

    Feasibility and completion of the Cancer-specific quality of life measured using the Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire.

    Time frame: Baseline

  6. Completion of the cancer-specific quality of life questionnaires

    Feasibility and completion of the Cancer-specific quality of life measured using the Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire.

    Time frame: 6 months post randomisation

  7. Completion of the cancer-specific quality of life questionnaires

    Feasibility and completion of the Cancer-specific quality of life measured using the Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire.

    Time frame: 12-months post randomisation

  8. Completion of healthcare and social care resource use questionnaires

    This will be a bespoke patient questionnaire on primary and secondary healthcare and social care resource use.

    Time frame: 6 months post randomisation

  9. Completion of healthcare and social care resource use questionnaires

    This will be a bespoke patient questionnaire on primary and secondary healthcare and social care resource use.

    Time frame: 12-months post randomisation

  10. Total hospital stays including readmission

    Recorded from medical notes and healthcare resource use form.

    Time frame: 12-months post randomisation

Other outcomes

  1. Quantity of circulating free DNA

    Change from baseline quantity of circulating free DNA at treatment completion

    Time frame: Day 3 hospital stay

  2. DNA whole-genome sequencing

    Quantitative genomic analysis of the blood cells to study the characteristics and investigate the technical feasibility of this for the future definitive trial.

    Time frame: Day 3 hospital stay

  3. Quantity of circulating tumour cells

    Change from baseline circulating tumour cells quantity at treatment completion

    Time frame: Day 3 hospital stay

  4. Circulating tumour cells functional characteristics

    Comparison between lidocaine and placebo treatment group

    Time frame: Day 3 hospital stay

  5. Pro-inflammatory cytokine levels

    Change from baseline pro-inflammatory cytokine levels at treatment completion

    Time frame: Day 3 hospital stay

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Sep 2024, 19 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 19 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 22, 2022
StartActual
Feb 2, 2023
Primary completionEst.
Sep 15, 2024
CompletionEst.
Sep 15, 2024
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05250791
Responsible party
Sponsor
First posted
Feb 22, 2022
Start date
Feb 2, 2023
Primary completion
Sep 15, 2024 (estimated)
Completion
Sep 15, 2024 (estimated)
Last update
Jun 9, 2023

Study contacts

West Raha, MBChB
Contact
flicor.trial@imperial.ac.uk
07496833117
West Raha, MBChB
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion